• Interim CEO employment contract consists solely of equity compensation • Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m …
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
BOSTON and LONDON – June 4, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for …
[Read more...] about Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024
AGM VOTING RESULTS (FORM 8-K) NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL …
[Read more...] about NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for …
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune …
[Read more...] about Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
